Understanding Bile Acid Malabsorption: A Complete Guide to Causes, Diagnosis, and Treatment of Bile Acid–Related Chronic Diarrhea

Table of Contents

• Key Points
• Introduction: Why This Research Matters
• The Science Behind Bile Acid Malabsorption
• The Four Types of Bile Acid Malabsorption
• How Common Is BAM and Who Is Most at Risk?
• Study Methods: How This Review Was Conducted
• Diagnosing BAM: Available Tests and Their Accuracy
• Treatment Options for Bile Acid Malabsorption
• Clinical Implications: Why Accurate Diagnosis Matters
• Limitations of Current Knowledge
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• BAM affects 25–35% of unexplained chronic diarrhea cases and about 30% of IBS-D patients.
• Up to half of BAM patients wait over five years for an accurate diagnosis.
• 75SeHCAT is described as the most accurate test, but it is not widely available.
• Bile acid sequestrants improve symptoms in 96% of severe BAM and 70% of mild BAM in IBS-D patients.
• BAM subtypes include ileal disease, idiopathic, non-ileal conditions, and excessive bile acid synthesis.

Introduction: Why This Research Matters

Bile acid malabsorption (BAM) is an important disorder of the digestive system that causes chronic diarrhea — a condition the original authors describe as "cholorrhea." It occurs when the body either produces too many bile acids or fails to absorb them properly in the final section of the small intestine (the terminal ileum) or in the colon. When excess bile acids reach the lower gastrointestinal tract, they trigger a cascade of problems: abnormal transport of water and sodium, damage to the intestinal lining, increased mucus secretion, faster intestinal motility, and an unhealthy shift in gut bacteria (gut dysbiosis).

The symptoms of BAM can be distressing and life-altering. Patients often experience:

• A strong, sudden urge to defecate (urge of defecation)
• Fecal incontinence (accidental bowel leakage)
• Fatigue and tiredness
• Dizziness and fainting feelings

Many of these symptoms can resemble those seen in disorders of gut–brain interaction (formerly known as functional gastrointestinal disorders). However, the review authors emphasize that an accurate diagnosis of BAM can greatly benefit the patient. Left unrecognized and untreated, BAM is linked to depression and a significantly reduced quality of life.

One of the most striking findings of this review is the problem of diagnostic delay. Up to one-half of patients with BAM report having symptoms for more than five years before the correct diagnosis is made. The authors call timely and accurate identification of BAM "a major unmet need."

The Science Behind Bile Acid Malabsorption

To understand BAM, it helps to understand the journey of bile acids through the body. Bile acids are produced in the liver from cholesterol. The primary bile acids — cholic acid (CA) and chenodeoxycholic acid (CDCA) — are synthesized mainly by the enzyme cholesterol 7α-hydroxylase (CYP7A1) and by CYP8B1 in what is called the "classical pathway," with an alternative pathway mediated by CYP27A1. These bile acids are then attached (conjugated) to the amino acids taurine or glycine, a process involving two enzymes: BA-CoA synthase (BACS) and BA-CoA-amino acid N-acetyltransferase (BAAT).

Once conjugated, bile acids are secreted into bile through the bile salt export pump (BSEP), where they play a crucial role in digesting fats. The gallbladder stores and concentrates bile, releasing it into the duodenum when needed. During fasting, about 20% of the gallbladder's contents empty at the end of phase II of the migrating myoelectric complex, under the control of the vagus nerve and the hormone motilin. After a meal, more than 50% emptying occurs due to fat-induced release of the enterohormone cholecystokinin (CCK).

In healthy people, fasting serum bile acid concentrations range from 0.2 to 0.7 μM, rising to 4–5 μM after each meal. The enterohepatic circulation (the recycling system between the intestine and liver) involves 4 to 12 cycles of bile acids daily.

In the terminal ileum, bile acids bind to a key receptor called the farnesoid X receptor (FXR). This activates the release of fibroblast growth factor 19 (FGF19), which travels through the portal circulation to the liver, where it binds to FGFR4/β-Klotho receptors. This signaling inhibits the expression of CYP7A1 and CYP8B1, thereby reducing further bile acid synthesis — a negative feedback loop that keeps bile acid production in check.

Bile acids in the intestine also activate another receptor called GPBAR-1 (G-protein bile acid receptor-1), which stimulates the secretion of peptide YY (PYY), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2). These hormones have important metabolic effects on glucose metabolism, insulin regulation, and appetite.

Normally, more than 95% of bile acids are efficiently reabsorbed in the terminal ileum. The remaining 5% enter the colon, where gut bacteria transform them into secondary bile acids. Only about 5% of bile acids are lost in the feces daily. However, when this finely tuned system breaks down — whether from ileal disease, excessive bile acid production, or other causes — excess bile acids spill into the colon. There, they cause the watery diarrhea and related symptoms characteristic of BAM.

The Four Types of Bile Acid Malabsorption

BAM is classified into four subtypes based on the underlying cause:

Type 1: Ileal Disease — This type results from defective bile acid reabsorption due to disease or removal of the terminal ileum. It is frequently seen in Crohn's disease, with or without ileal resection. The prevalence of Type 1 BAM in Crohn's disease ranges from 11% to 76%. It may also occur in patients undergoing ileal resection for any reason and due to radiation enteropathy (radiation-induced intestinal damage). Type 1 BAM can manifest as osmotic diarrhea or as true steatorrhea (fatty stool) secondary to fat malabsorption. In patients with chronic watery diarrhea, Type 1 BAM prevalence measured by 75SeHCAT testing was 34%.

Type 2: Idiopathic (Primary) BAM — In this type, no defect in bile acid absorption can be documented, yet the patient experiences bile acid diarrhea. It may present as primary bile acid diarrhea or as the diarrheal variant of irritable bowel syndrome (IBS-D). Type 2 is associated with reduced microbial transformation of primary to secondary bile acids. Rare genetic variants account for approximately 1% of primary BAM cases. Specific genetic findings include:

• The rs3808607 T>G polymorphism in the CYP7A1 gene promoter region, which is associated with elevated C4-to-cholesterol ratios in patients who develop secondary BAD after ileal resection surgery. Individuals carrying the TT (AA) genotype may have a twofold increase in bile acid synthesis.
• The rs8192877 A>G variant, where heterozygotes exhibit approximately double the fecal primary bile acids compared to AA homozygotes, with even higher levels in GG homozygotes.
• Variants that alter ASBT (the apical sodium-dependent bile acid transporter), reduce FGF19 synthesis, and impair inhibition of bile acid synthesis in the liver.
• Genetic polymorphisms of FGFR4-β-Klotho variations and dysregulated FGF19 response, with significant associations with primary BAD and IBS-D due to increased bile acid synthesis.
• A variant of GPBAR-1, SNP rs11554825 (minor allele frequency of 41%), which correlated with symptoms in a study comparing 230 healthy controls and 414 patients with functional gastrointestinal disorders (84 IBS alternators, 157 IBS-C, and 173 IBS-D).

The prevalence of Type 2 BAM is estimated in few studies to be as low as 1% of new cases of chronic diarrhea and 3% of patients with overall chronic diarrhea, suggesting significant underdiagnosis. However, 51% of patients with unexplained diarrhea who underwent 48-hour fecal bile acid testing had BAM. Notably, about two-thirds of these patients improved with bile acid sequestrant therapy, while only one-third improved when BAM was absent.

In patients with chronic diarrhea tested by 75SeHCAT, BAM was detected in 38% of cases, with Type 2 accounting for 28% of cases. Other researchers report that BAM tested by 75SeHCAT is found in 50% of patients, one-third of whom have IBS-D.

Type 3: Non-Ileal Conditions Leading to BAM — This type occurs in patients with conditions that are not directly related to ileal disease but nonetheless lead to bile acid malabsorption. In patients with chronic watery diarrhea, Type 3 BAM prevalence by 75SeHCAT was 28%. Key examples include:

Post-cholecystectomy diarrhea: After gallbladder removal, patients experience post-prandial release of a more continuous drip of less concentrated bile acids. Cholecystectomized individuals show about double the recycling of the bile acid pool through the intestine, which is associated with a twofold increase in bile acid synthesis and increased bile acid and cholesterol biliary secretion rates. Although the bile acid pool remains constant and fat is digested and absorbed normally, increased exposure of primary bile acids to gut bacteria leads to their conversion to secondary bile acids, mainly deoxycholic acid (DCA). DCA can disrupt cell membranes, leading to cell lysis. The incidence of diarrhea after cholecystectomy has a wide range — from 2% to 50% — depending on the population studied, the study design, and how diarrhea is characterized. The diarrhea usually resolves or improves over weeks to months after surgery. Some authors report BAM incidence of 68–86% after cholecystectomy, but a larger analysis of 25 studies found only 9.1% of patients experienced diarrhea after cholecystectomy (two-thirds of those diagnosed with BAM).

Other causes of Type 3 BAM include post-vagotomy diarrhea (diarrhea after surgery on the vagus nerve for ulcers), chronic pancreatitis with impaired bicarbonate secretion, and celiac disease, which causes villous atrophy and impaired bile acid absorption.

Microscopic colitis: Bile acid malabsorption in microscopic colitis depends on villous atrophy, inflammation, and collagen deposition in the ileum. 75SeHCAT retention of less than 10% has been found in about 44% of patients with collagenous colitis and chronic diarrhea, and almost 80% were responsive to bile acid sequestrant therapy. The authors suggest considering therapy in all patients with microscopic colitis even if the 75SeHCAT test is negative.

Type 4: Excessive Bile Acid Synthesis — This type occurs with excessive bile acid production without primary malabsorption. It is essentially seen in hypertriglyceridemia and during antidiabetic therapy with metformin. About 20% of patients on metformin have accelerated bowel transit times. Increased hepatic bile acid production and diarrhea also occur in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), who also display elevated serum C4 levels. Patients with obesity and hypertriglyceridemia can show increased bile acid synthesis and idiopathic BAM.

How Common Is BAM and Who Is Most at Risk?

In a US population study of patients referred to a gastroenterology outpatient clinic, the prevalence of chronic diarrhea was about 1%. Among patients with unexplained chronic diarrhea, the prevalence of BAM is approximately 25% to 35%. Additionally, about 30% of patients being treated for diarrhea-predominant irritable bowel syndrome (IBS-D) actually suffer from idiopathic BAM.

The prevalence of BAM is even higher in patients with risk factors for the condition, such as:

• Patients undergoing ileal resection
• Patients with terminal ileal diseases (e.g., Crohn's disease, radiation-induced injury)
• Patients with gastrointestinal diseases associated with impaired motility or absorption, such as celiac disease
• Patients with dysregulated delivery of bile acids to the small intestine, as seen after cholecystectomy (gallbladder removal)
• Patients with post-vagotomy diarrhea, who show higher fecal bile acid excretion

A notable Danish study conducted between 2003 and 2021 identified 5,264 individuals affected by BAM based on 75SeHCAT testing. When compared to age- and sex-matched controls from the general population, those in the BAM cohort exhibited a higher prevalence of comorbidities, increased healthcare utilization, and lower levels of education and income. This suggests that BAM imposes a substantial burden not only on individual health but also on the healthcare system and socioeconomic well-being.

A systematic review estimated the population prevalence of BAM at greater than 1%, with the condition found in about 30% of patients with chronic diarrhea when tested by 75SeHCAT.

In a synthesis of 15 prospective studies of patients with IBS-D-like symptoms, the prevalence of BAM by 75SeHCAT testing was:

• Severe BAM: 10%
• Moderate BAM: 32%
• Mild BAM: 26%

The response rate to the bile acid sequestrant cholestyramine was 96% in patients with severe BAM and 70% in patients with mild BAM. About one-fourth of patients with IBS-D or functional diarrhea are positive for bile acid diarrhea. Other studies have reported an association between BAM and post-infective diarrhea — 55% of patients with a history of acute gastroenteritis had a positive 75SeHCAT test, and 18% of patients with post-infective diarrhea and BAM responded to cholestyramine. Fecal levels of primary unconjugated bile acids and serum C4 were high in patients with IBS-D who secreted more bile acids, but lower in patients with IBS with constipation (IBS-C) or in healthy volunteers. This points to a clear role for bile acids in the pathogenesis of IBS, with serum C4 and primary and secondary unconjugated fecal bile acids serving as potential biomarkers of BAM.

Study Methods: How This Review Was Conducted

The authors conducted a systematic literature search in PubMed to identify studies on BAM published from 1965 to May 19, 2024. The search used a combination of keywords and Medical Subject Headings (MeSH) related to BAM, including: "bile acid malabsorption," "bile acid diarrhoea," "bile salt malabsorption," "bile salt diarrhoea," and "BAM," combined with "diarrhoea," "chronic diarrhoea," and "malabsorptive diarrhoea."

Studies were included if they: (1) focused on BAM and its association with bile acid–induced diarrhea, and (2) provided original data. Reviews, editorials, and letters were excluded unless they contained relevant data. The authors also analyzed the reference lists of selected articles to identify additional studies that may have been missed during the initial search.

Diagnosing BAM: Available Tests and Their Accuracy

BAM and related diarrhea are frequently underdiagnosed conditions, and early diagnosis is essential to avoid unnecessary diagnostic tests and to improve quality of life. While all available tests have limitations, they can help identify cases that will most benefit from treatment. Unfortunately, these tests are rarely used in combination due to their limited availability and cost. The review discusses six approaches to diagnosis.

1. Empiric Use of Bile Acid Sequestrants

This approach involves giving patients a trial of bile acid sequestrants (medications that bind to bile acids in the intestine) and assessing the clinical response. It is recommended in patients with unexplained chronic diarrhea when other specific tests are not available. However, studies comparing the accuracy of the empiric approach versus specific testing are missing. The most important limitation is the scarce compliance of patients, with false-negative results possibly depending on the poor palatability of bile acid sequestrants.

2. 75SeHCAT Test

The 75Selenium HomotauroCholic Acid Test (75SeHCAT) is described as the most accurate test to identify the presence and severity of BAM. This nuclear medicine test relies on the assessment of abdominal retention of bile acids 7 days after ingestion of a synthetic conjugated bile acid (homotaurocholic acid) labeled with the 75selenium (Se) isotope.

The test procedure involves:

1. Avoiding bile acid sequestrant therapy for a few days before the test
2. Fasting for 4 hours before ingesting the 75SeHCAT capsule
3. A first scan with a gamma camera within 3 hours of ingestion
4. A second scan 7 days later

The 7-day interval makes the test less dependent on daily dietary effects. Fecal bile acid loss is indicated by low retention of 75SeHCAT. BAM is classified by the percentage of retained radioactive selenium:

• Severe BAM: less than 5% retention
• Moderate BAM: 5–10% retention
• Mild BAM: 10–15% retention

In a systematic review of 43 studies enrolling 1,223 IBS patients, the less than 5%, less than 10%, and less than 15% retention thresholds were found in 10%, 27%, and 13% of the cohort, respectively.

The test involves limited radiation exposure: 75SeHCAT activity is small (370 kBq), the radiation dose is 0.26 mSv, and the total absorbed radiation is 0.3 Gy/kBq. Despite its high diagnostic accuracy, 75SeHCAT is not widely available and is not accessible for most clinicians. It requires a nuclear medicine department with trained personnel and is time-consuming for the patient. These limitations may lead to missed diagnosis, diagnostic delay, or unnecessary radiological and endoscopic examinations.

3. Fecal Bile Acids Test

The direct measurement of bile acids that reach the colon and are excreted in the feces is a useful alternative when 75SeHCAT is not available. The test is performed after a four-day diet containing 100 grams of fat, followed by a 48-hour stool collection to measure total and individual amounts of fecal bile acids.

There are two recommended cut-off criteria for diagnosing BAM:

• Total fecal bile acid excretion in excess of 2,337 µmol per 48 hours, or a fraction of primary bile acids (CDCA and CA) exceeding 10% of the total
• Total fecal bile acid excretion in excess of 1,000 µmol per 48 hours, plus a fraction of primary bile acids exceeding 4%

Stool frequency and consistency correlate with concentrations of primary fecal bile acids. While the test is simple and safe, both patients and healthcare workers may find the methodology time-consuming and inconvenient. The test has a sensitivity of 45% and a specificity of 63% for detecting 75SeHCAT retention of less than 15% when combined with primary bile acids exceeding 10%. Determining individual bile acid species is mainly reserved for experimental purposes, as the simple assessment of total fecal bile acids is a satisfactory option for clinical practice.

4. Fasting Serum 7α-Hydroxy-4-Cholesten-3-One (C4)

C4 is the precursor of hepatic bile acid synthesis, and fasting serum C4 level is a direct measure of the activity of this pathway. A C4 level greater than 48.9 ng/mL can indicate the presence of BAM. The measurement of C4 and FGF19 (the interdependent inhibitor of bile acid synthesis) has been validated against 75SeHCAT.

Because of typical diurnal fluctuations in C4 levels, blood sampling must occur before 9 am. False-positive or false-negative results are possible in patients with cholestatic chronic liver disease, hypertriglyceridemia, and in those using statins, as all of these conditions can interfere with bile acid synthesis. C4 serum levels can also change in response to factors affecting circadian rhythm, which impacts bile acid synthesis. Due to possible confounders in the isolated diagnostic use of fasting C4 levels, the authors recommend combination testing for diagnostic purposes — for example, fecal bile acids plus C4 levels.

5. Fasting Serum Fibroblast Growth Factor 19 (FGF19)

Decreased FGF19 is associated with a decrease in the inhibition of the conversion of cholesterol to bile acids. The diagnosis of BAM relies on decreased FGF19 levels alongside elevated C4 levels. Serum levels of FGF19 may be used as an index of ileal bile acid reabsorption.

When measured in patients with chronic diarrhea, the cut-off value of fasting FGF19 to ascertain the diagnosis of BAM is set at less than 60 pg/mL. Like C4 measurements, FGF19 requires morning sampling in the fasting subject.

6. Emerging Diagnostic Tests

Several novel experimental tests are being developed for the diagnosis of BAM, but supplemental evidence is still needed. These include:

• Molecular imaging techniques that analyze the binding of different bile acids to GPBAR-1 and FXR receptors
• Serum lipidome profiles, which may distinguish individuals with BAM
• Detection of microbial metabolites as volatile organic compounds (VOCs), offering novel possibilities to mark gut dysbiosis in BAM compared to healthy individuals

This methodology is described as appealing and promising, but it requires complex experimental procedures, standardization, and data analysis. The authors note that more validation studies, including machine learning techniques, are required in this field. The current scarcity of reliable and widely available diagnostic tests represents an unmet need, particularly in cases where the diagnostic utility of bile acid sequestrants is insufficient to confirm the diagnosis of BAM.

Treatment Options for Bile Acid Malabsorption

The management of BAM must consider the underlying condition if a cause has been identified. In cases with unknown etiology, current therapeutic approaches include dietary modifications and bile acid sequestrants (BASTs).

Bile acid sequestrants (also called bile acid binders) work by binding to bile acids in the intestine, preventing them from triggering diarrhea. They include medications such as cholestyramine, colestipol, and colesevelam. The review notes that bile acid sequestrant therapy improves scores for the "Role limitation due to physical health" dimension and the overall mental component summary, as measured by the 36-Item Short Form Survey (SF-36), a widely used quality-of-life questionnaire.

Supporting evidence for treatment comes from an Italian retrospective study of chronic diarrhea in 136 patients with ileal disease, cholecystectomy, or post-prandial diarrhea. BAM was confirmed in 28.1% of cases, and subjects improved after 6-month treatment with cholestyramine.

A systematic review of 30 studies collecting data from 1,241 patients with established bile acid diarrhea and treated with bile acid sequestrants reported positive treatment responses across the included studies.

Beyond bile acid sequestrants, the review highlights several novel therapeutic approaches on the horizon:

• FXR agonists — medications that activate the farnesoid X receptor to help regulate bile acid production
• FGF19 analogues — synthetic versions of fibroblast growth factor 19 that can inhibit bile acid synthesis
• GLP-1 receptor agonists — a class of medications that affects bile acid signaling and metabolism (some of which are already used in diabetes and obesity treatment)
• Microbiota modulation — strategies to restore a healthy balance of gut bacteria, which play a key role in bile acid transformation

The authors argue that these novel agents can best make their way into the therapeutic toolkit if BAM is no longer treated as a diagnosis of exclusion. Ignoring BAM as a specific condition may continue to contribute to increased healthcare costs and reduced quality of life.

Clinical Implications: Why Accurate Diagnosis Matters

The findings of this review have significant implications for patients and clinicians alike. First, BAM is far more common than generally recognized. With 25–35% of unexplained chronic diarrhea cases attributable to BAM, and roughly 30% of IBS-D patients having idiopathic BAM, this condition should be high on the list of possibilities when evaluating chronic diarrhea.

Second, the diagnostic delay is unacceptable. Up to half of patients suffer for over five years before getting the right diagnosis. During this time, they may undergo unnecessary and invasive radiological and endoscopic examinations, and the condition takes a toll on mental health, quality of life, and even socioeconomic status, as the Danish study of 5,264 patients demonstrated. That study found BAM patients had lower education and income levels and higher healthcare utilization compared to matched controls.

Third, accurate diagnosis matters because BAM is treatable. Bile acid sequestrants are effective, with response rates of 96% in severe BAM and 70% in mild BAM among IBS-D patients. Even in microscopic colitis, about 80% of patients with collagenous colitis responded to bile acid sequestrant therapy. The confirmation of BAM through specific testing leads to more targeted and effective management.

The authors emphasize that timely and accurate identification of BAM is a major unmet need in gastroenterology.

Limitations of Current Knowledge

While this systematic review provides a comprehensive overview of BAM, the authors acknowledge several important limitations in the current body of knowledge:

• Limited availability of diagnostic tests: The most accurate test, 75SeHCAT, is not widely available and requires specialized nuclear medicine facilities. Many clinicians cannot access it for their patients.
• Lack of diagnostic standardization: The absence of standardized diagnostic criteria may account for poor recognition and delayed management of BAM.
• Few prevalence estimates: Type 2 BAM prevalence is estimated in only a few studies, with figures as low as 1% of new chronic diarrhea cases, suggesting significant underdiagnosis.
• Confounders in testing: C4 levels can be affected by cholestatic liver disease, hypertriglyceridemia, statin use, and circadian rhythm factors. F

  Frequently Asked Questions

  What is bile acid malabsorption (BAM)?

  Bile acid malabsorption (BAM) is a digestive disorder where the body produces too many bile acids or fails to absorb them properly in the terminal ileum or colon. Excess bile acids reach the lower gut, causing water and sodium transport problems, intestinal damage, faster motility, and unhealthy gut bacteria, leading to chronic diarrhea and related symptoms.

  How is bile acid malabsorption diagnosed?

  Doctors may use an empiric trial of bile acid sequestrants, or specific tests. The 75SeHCAT test measures bile acid retention and is described as the most accurate. Alternative tests include 48-hour fecal bile acid measurement, fasting serum C4, and fasting serum FGF19 levels. Each test has limitations and may not be widely available.

  What are the four types of bile acid malabsorption?

  Type 1 results from ileal disease or removal, such as Crohn's disease. Type 2 is idiopathic (primary) BAM, often linked to IBS-D. Type 3 occurs with other conditions like post-cholecystectomy diarrhea, celiac disease, or microscopic colitis. Type 4 is excessive bile acid synthesis, seen with hypertriglyceridemia or metformin therapy.

  What treatments are available for bile acid malabsorption?

  Current treatments include bile acid sequestrants like cholestyramine, colestipol, and colesevelam, which bind bile acids in the intestine. Dietary modifications may help. Newer approaches under study include FXR agonists, FGF19 analogues, GLP-1 receptor agonists, and microbiota modulation, but these are not yet standard clinical treatments.

  Why can it take years to get a diagnosis of bile acid malabsorption?

  Up to half of patients with BAM have symptoms for more than five years before receiving the correct diagnosis, according to the review. This delay occurs because symptoms resemble other gut disorders, diagnostic tests like 75SeHCAT are not widely available, and clinicians may not consider BAM, leading to unnecessary invasive procedures.

  I was diagnosed with IBS-D but chronic diarrhea continues—could it be bile acid malabsorption and should I seek a second opinion?

  If chronic diarrhea continues despite a diagnosis of IBS-D, bile acid malabsorption (BAM) may be the cause. About 30% of patients treated for diarrhea-predominant IBS-D actually have idiopathic BAM. Symptoms often mimic IBS-D, and up to half of BAM patients wait more than five years for the right diagnosis. Specific tests, including 75SeHCAT, fecal bile acid measurement, serum C4, and FGF19, can confirm BAM. Bile acid sequestrants improve severe BAM in 96% of cases. A second opinion can ensure these tests are considered. Diagnostic Detectives Network provides independent expert second opinions.